GLP1R and type 2 diabetes mellitus: The current meta-analysis aims to bridge this gap, examining the association between GLP-1 receptor agonists and a broader range of malignant neoplasms, thereby aiming to enhance the understanding of their safety profile and address the critical concerns related to cancer risks in patients with type 2 diabetes [1,2,3].